Dapagliflozin in STEMI
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation
About this trial
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.
Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo.
Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Eligibility criteria
Qualifiers
Ischemic chest discomfort of ≥30 minutes duration, and
Onset of chest pain ≤12 hours prior to entry into the study, and
Disqualifiers
Age < 18 years
Any contraindication to undergo CMR imaging
Killip 4 (Cardiogenic shock on presentation)
Therapy with SGLT2i within last 8 weeks
Trial design
Treatments tested in this trial
- Dapagliflozin 10mg Tab
- CMR
Treatment groups
256 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov